| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus Infections | 96 | 2025 | 344 | 14.830 |
Why?
|
| Respiratory Syncytial Virus, Human | 59 | 2025 | 206 | 12.780 |
Why?
|
| Bronchiolitis | 53 | 2022 | 122 | 8.170 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 24 | 2025 | 70 | 5.820 |
Why?
|
| Influenza, Human | 45 | 2024 | 662 | 4.720 |
Why?
|
| Antibodies, Viral | 54 | 2025 | 1150 | 4.370 |
Why?
|
| Respiratory Syncytial Viruses | 35 | 2025 | 147 | 4.280 |
Why?
|
| Respiratory Tract Infections | 26 | 2024 | 274 | 4.090 |
Why?
|
| Viral Fusion Proteins | 18 | 2023 | 76 | 3.100 |
Why?
|
| Influenza Vaccines | 30 | 2023 | 480 | 3.010 |
Why?
|
| Picornaviridae Infections | 17 | 2024 | 48 | 2.790 |
Why?
|
| Antiviral Agents | 22 | 2025 | 766 | 2.560 |
Why?
|
| Antibodies, Neutralizing | 23 | 2023 | 469 | 2.500 |
Why?
|
| Viral Load | 17 | 2025 | 389 | 2.400 |
Why?
|
| Bronchiolitis, Viral | 14 | 2021 | 30 | 2.250 |
Why?
|
| Nasopharynx | 22 | 2022 | 80 | 2.170 |
Why?
|
| Infant | 138 | 2025 | 12610 | 2.160 |
Why?
|
| Rhinovirus | 20 | 2022 | 59 | 2.150 |
Why?
|
| Viruses | 9 | 2024 | 121 | 2.130 |
Why?
|
| Hospitalization | 41 | 2024 | 1783 | 2.080 |
Why?
|
| Virus Diseases | 10 | 2022 | 280 | 1.930 |
Why?
|
| Enterovirus | 3 | 2024 | 52 | 1.540 |
Why?
|
| Viral Vaccines | 11 | 2015 | 337 | 1.410 |
Why?
|
| Humans | 234 | 2025 | 125025 | 1.380 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 71 | 1.370 |
Why?
|
| Enterovirus Infections | 2 | 2024 | 49 | 1.370 |
Why?
|
| Metapneumovirus | 8 | 2022 | 50 | 1.340 |
Why?
|
| Respiratory Sounds | 13 | 2021 | 70 | 1.290 |
Why?
|
| Prospective Studies | 56 | 2025 | 6122 | 1.210 |
Why?
|
| Transplant Recipients | 3 | 2021 | 218 | 1.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 1097 | 1.140 |
Why?
|
| Female | 138 | 2025 | 66669 | 1.090 |
Why?
|
| Dibenzothiepins | 3 | 2023 | 3 | 1.080 |
Why?
|
| Child, Preschool | 78 | 2025 | 14150 | 1.020 |
Why?
|
| Immunoglobulin G | 10 | 2021 | 780 | 0.990 |
Why?
|
| Male | 126 | 2025 | 61429 | 0.990 |
Why?
|
| Bodily Secretions | 2 | 2016 | 7 | 0.970 |
Why?
|
| Nanoparticles | 8 | 2025 | 230 | 0.960 |
Why?
|
| Palivizumab | 6 | 2021 | 47 | 0.950 |
Why?
|
| Neutralization Tests | 14 | 2016 | 236 | 0.950 |
Why?
|
| Microbiota | 11 | 2022 | 384 | 0.940 |
Why?
|
| Infant, Newborn | 45 | 2025 | 8272 | 0.940 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 9 | 2019 | 178 | 0.920 |
Why?
|
| Vaccines, Attenuated | 15 | 2019 | 175 | 0.920 |
Why?
|
| Orthomyxoviridae | 8 | 2023 | 51 | 0.910 |
Why?
|
| Triazines | 3 | 2023 | 30 | 0.910 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2023 | 115 | 0.910 |
Why?
|
| RNA, Viral | 10 | 2024 | 537 | 0.900 |
Why?
|
| Immunoglobulin A | 4 | 2021 | 207 | 0.890 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2014 | 61 | 0.870 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 325 | 0.860 |
Why?
|
| Pyridones | 3 | 2023 | 118 | 0.850 |
Why?
|
| Morpholines | 2 | 2020 | 59 | 0.840 |
Why?
|
| Adult | 50 | 2025 | 29452 | 0.830 |
Why?
|
| Cystic Fibrosis | 7 | 2007 | 259 | 0.820 |
Why?
|
| Adenoviridae | 13 | 2022 | 603 | 0.800 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2016 | 770 | 0.780 |
Why?
|
| Immunity, Mucosal | 2 | 2025 | 87 | 0.770 |
Why?
|
| Cytokines | 8 | 2024 | 1292 | 0.760 |
Why?
|
| Seasons | 10 | 2024 | 312 | 0.760 |
Why?
|
| Asthma | 11 | 2021 | 756 | 0.750 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 48 | 0.730 |
Why?
|
| Virus Replication | 14 | 2025 | 607 | 0.710 |
Why?
|
| Child | 63 | 2024 | 24609 | 0.700 |
Why?
|
| Antigens, Viral | 10 | 2024 | 438 | 0.690 |
Why?
|
| Disease Outbreaks | 7 | 2023 | 320 | 0.680 |
Why?
|
| Vaccination | 17 | 2023 | 961 | 0.660 |
Why?
|
| Nasal Mucosa | 5 | 2024 | 66 | 0.630 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2024 | 61 | 0.630 |
Why?
|
| Bacterial Infections | 2 | 2019 | 304 | 0.620 |
Why?
|
| Community-Acquired Infections | 3 | 2013 | 241 | 0.620 |
Why?
|
| Bordetella pertussis | 2 | 2016 | 16 | 0.610 |
Why?
|
| Influenza B virus | 7 | 2015 | 87 | 0.590 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2014 | 35 | 0.590 |
Why?
|
| Cohort Studies | 24 | 2024 | 4819 | 0.590 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2019 | 454 | 0.580 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 226 | 0.580 |
Why?
|
| Adolescent | 42 | 2024 | 19412 | 0.580 |
Why?
|
| Real-Time Polymerase Chain Reaction | 9 | 2021 | 508 | 0.570 |
Why?
|
| Genes, Viral | 2 | 2017 | 184 | 0.560 |
Why?
|
| Genotype | 10 | 2021 | 2569 | 0.560 |
Why?
|
| Adenoviridae Infections | 4 | 2008 | 71 | 0.550 |
Why?
|
| Virus Shedding | 5 | 2021 | 81 | 0.550 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2022 | 152 | 0.550 |
Why?
|
| Texas | 14 | 2021 | 3571 | 0.550 |
Why?
|
| Paramyxoviridae Infections | 6 | 2022 | 46 | 0.540 |
Why?
|
| Length of Stay | 11 | 2017 | 1305 | 0.540 |
Why?
|
| Adenovirus Infections, Human | 5 | 2003 | 50 | 0.530 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 377 | 0.530 |
Why?
|
| Adjuvants, Immunologic | 9 | 2025 | 381 | 0.520 |
Why?
|
| Sigmodontinae | 13 | 2025 | 44 | 0.520 |
Why?
|
| Severity of Illness Index | 23 | 2022 | 2905 | 0.520 |
Why?
|
| Viral Proteins | 6 | 2016 | 346 | 0.510 |
Why?
|
| Immunization Programs | 4 | 2008 | 63 | 0.500 |
Why?
|
| Adenoviruses, Human | 4 | 2003 | 81 | 0.500 |
Why?
|
| Young Adult | 21 | 2021 | 9054 | 0.500 |
Why?
|
| Genome, Viral | 4 | 2024 | 165 | 0.490 |
Why?
|
| Influenza A virus | 11 | 2015 | 138 | 0.480 |
Why?
|
| Lung | 13 | 2025 | 1490 | 0.480 |
Why?
|
| Nasal Lavage Fluid | 3 | 2016 | 14 | 0.470 |
Why?
|
| Common Cold | 4 | 2019 | 22 | 0.470 |
Why?
|
| Vaccines, Synthetic | 8 | 2020 | 316 | 0.470 |
Why?
|
| Whooping Cough | 1 | 2015 | 60 | 0.460 |
Why?
|
| Infant, Premature, Diseases | 3 | 2010 | 245 | 0.440 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2014 | 81 | 0.440 |
Why?
|
| Administration, Intranasal | 13 | 2025 | 132 | 0.440 |
Why?
|
| Antibody Formation | 6 | 2021 | 265 | 0.430 |
Why?
|
| Caspases | 1 | 2014 | 163 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 509 | 0.410 |
Why?
|
| Coinfection | 5 | 2024 | 172 | 0.410 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 53 | 0.410 |
Why?
|
| HN Protein | 3 | 1998 | 18 | 0.390 |
Why?
|
| Metabolome | 5 | 2021 | 293 | 0.390 |
Why?
|
| Middle Aged | 26 | 2025 | 26670 | 0.390 |
Why?
|
| Infant, Premature | 3 | 2020 | 833 | 0.390 |
Why?
|
| Coronavirus | 3 | 2022 | 25 | 0.390 |
Why?
|
| Vaccines, Inactivated | 6 | 2019 | 144 | 0.390 |
Why?
|
| Pregnancy | 14 | 2022 | 7215 | 0.370 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2017 | 38 | 0.370 |
Why?
|
| Phenotype | 1 | 2021 | 4266 | 0.370 |
Why?
|
| Oseltamivir | 2 | 2022 | 16 | 0.370 |
Why?
|
| United States | 23 | 2025 | 10884 | 0.350 |
Why?
|
| Immunity, Herd | 3 | 2010 | 12 | 0.340 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 187 | 0.340 |
Why?
|
| Drug Resistance, Viral | 5 | 2022 | 47 | 0.340 |
Why?
|
| Lung Diseases | 5 | 2016 | 385 | 0.330 |
Why?
|
| Nasal Cavity | 4 | 2018 | 50 | 0.320 |
Why?
|
| Cell Line | 8 | 2023 | 2717 | 0.320 |
Why?
|
| Cost of Illness | 2 | 2025 | 251 | 0.320 |
Why?
|
| Respiratory Tract Diseases | 5 | 2022 | 75 | 0.320 |
Why?
|
| Intubation, Intratracheal | 2 | 2012 | 286 | 0.310 |
Why?
|
| Eczema | 2 | 2021 | 29 | 0.310 |
Why?
|
| Cross Infection | 4 | 2021 | 313 | 0.310 |
Why?
|
| Double-Blind Method | 10 | 2020 | 1605 | 0.310 |
Why?
|
| Aged | 20 | 2021 | 19653 | 0.310 |
Why?
|
| Social Change | 1 | 2008 | 15 | 0.310 |
Why?
|
| Acute Disease | 8 | 2024 | 1095 | 0.300 |
Why?
|
| Single-Domain Antibodies | 2 | 2020 | 8 | 0.300 |
Why?
|
| Respirovirus Infections | 6 | 2017 | 19 | 0.300 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2019 | 360 | 0.290 |
Why?
|
| Vaccines, Virus-Like Particle | 2 | 2019 | 33 | 0.290 |
Why?
|
| Finland | 8 | 2021 | 42 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 5 | 2024 | 1762 | 0.290 |
Why?
|
| Pandemics | 6 | 2023 | 1112 | 0.280 |
Why?
|
| Ribavirin | 4 | 2003 | 85 | 0.280 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 1320 | 0.280 |
Why?
|
| Animals | 36 | 2025 | 34205 | 0.280 |
Why?
|
| Intensive Care Units | 5 | 2020 | 493 | 0.280 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3402 | 0.280 |
Why?
|
| Infant, Low Birth Weight | 3 | 2020 | 167 | 0.270 |
Why?
|
| Moraxella | 4 | 2019 | 14 | 0.270 |
Why?
|
| Liposomes | 2 | 2025 | 188 | 0.270 |
Why?
|
| Genetic Vectors | 8 | 2014 | 940 | 0.270 |
Why?
|
| Haemophilus | 4 | 2019 | 13 | 0.270 |
Why?
|
| Genetic Variation | 6 | 2021 | 1505 | 0.260 |
Why?
|
| Bronchodilator Agents | 4 | 2017 | 151 | 0.260 |
Why?
|
| Host-Pathogen Interactions | 3 | 2025 | 253 | 0.260 |
Why?
|
| Viral Envelope Proteins | 4 | 2020 | 152 | 0.250 |
Why?
|
| Protein Conformation | 2 | 2018 | 836 | 0.240 |
Why?
|
| Respiratory System | 3 | 2021 | 97 | 0.240 |
Why?
|
| Drug Discovery | 2 | 2018 | 171 | 0.240 |
Why?
|
| Streptococcus | 3 | 2019 | 59 | 0.230 |
Why?
|
| Fever | 3 | 2024 | 297 | 0.230 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2003 | 145 | 0.230 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2004 | 27 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 9 | 2025 | 998 | 0.220 |
Why?
|
| Organoids | 2 | 2024 | 269 | 0.220 |
Why?
|
| Child Welfare | 1 | 2004 | 65 | 0.220 |
Why?
|
| Critical Care | 5 | 2017 | 656 | 0.220 |
Why?
|
| Pregnancy Complications | 2 | 2022 | 515 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 1591 | 0.220 |
Why?
|
| Immunity, Innate | 3 | 2024 | 372 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 825 | 0.220 |
Why?
|
| Immunocompromised Host | 5 | 2017 | 292 | 0.220 |
Why?
|
| Placebos | 4 | 2019 | 237 | 0.210 |
Why?
|
| Acetamides | 1 | 2024 | 47 | 0.210 |
Why?
|
| Pharynx | 3 | 2016 | 66 | 0.210 |
Why?
|
| Incidence | 9 | 2021 | 3130 | 0.210 |
Why?
|
| Staphylococcus | 3 | 2018 | 68 | 0.210 |
Why?
|
| Poliovirus | 1 | 2023 | 47 | 0.210 |
Why?
|
| Sulfonamides | 2 | 2015 | 270 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2020 | 683 | 0.210 |
Why?
|
| Thiepins | 1 | 2023 | 1 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6535 | 0.200 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 58 | 0.200 |
Why?
|
| Respiratory Mucosa | 2 | 2020 | 91 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2015 | 306 | 0.200 |
Why?
|
| Bacteria | 2 | 2019 | 476 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 6 | 2018 | 1021 | 0.200 |
Why?
|
| Biomarkers | 5 | 2019 | 3105 | 0.200 |
Why?
|
| Amino Acid Sequence | 3 | 2017 | 2709 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 229 | 0.190 |
Why?
|
| Interleukin-4 | 2 | 2001 | 140 | 0.190 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 4405 | 0.180 |
Why?
|
| Formaldehyde | 2 | 1993 | 37 | 0.180 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 728 | 0.180 |
Why?
|
| Age Factors | 9 | 2019 | 2815 | 0.180 |
Why?
|
| Phylogeny | 5 | 2024 | 686 | 0.180 |
Why?
|
| Interferon-gamma | 2 | 2017 | 505 | 0.180 |
Why?
|
| Chemokine CCL5 | 2 | 2018 | 53 | 0.180 |
Why?
|
| Viremia | 3 | 2014 | 129 | 0.180 |
Why?
|
| Lipids | 1 | 2004 | 519 | 0.180 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2008 | 396 | 0.170 |
Why?
|
| Drug Compounding | 1 | 2020 | 36 | 0.170 |
Why?
|
| Rats | 9 | 2018 | 3723 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 153 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 1399 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 170 | 0.170 |
Why?
|
| Recurrence | 6 | 2021 | 1388 | 0.170 |
Why?
|
| Endonucleases | 1 | 2020 | 55 | 0.170 |
Why?
|
| Smoking | 3 | 2015 | 1049 | 0.170 |
Why?
|
| Antigenic Variation | 2 | 2017 | 39 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2017 | 390 | 0.170 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 205 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2016 | 1187 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.160 |
Why?
|
| Coxsackievirus Infections | 1 | 2019 | 10 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2004 | 504 | 0.160 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1716 | 0.160 |
Why?
|
| Vero Cells | 4 | 2020 | 109 | 0.160 |
Why?
|
| Peptides | 2 | 2021 | 812 | 0.160 |
Why?
|
| Treatment Outcome | 17 | 2020 | 12269 | 0.160 |
Why?
|
| Chile | 3 | 2017 | 22 | 0.160 |
Why?
|
| HEK293 Cells | 1 | 2021 | 737 | 0.160 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2017 | 108 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2020 | 3422 | 0.160 |
Why?
|
| Cities | 3 | 2024 | 47 | 0.150 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2019 | 52 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2019 | 124 | 0.150 |
Why?
|
| Immunoglobulin E | 2 | 2019 | 162 | 0.150 |
Why?
|
| Kinetics | 1 | 2021 | 1325 | 0.150 |
Why?
|
| Drug Carriers | 2 | 2014 | 99 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1294 | 0.150 |
Why?
|
| Risk Factors | 11 | 2021 | 10278 | 0.150 |
Why?
|
| Japan | 3 | 2023 | 135 | 0.150 |
Why?
|
| Respiration | 1 | 1999 | 122 | 0.150 |
Why?
|
| Global Health | 2 | 2020 | 570 | 0.150 |
Why?
|
| Laboratories | 1 | 2019 | 81 | 0.150 |
Why?
|
| Allografts | 1 | 2019 | 176 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2020 | 16334 | 0.150 |
Why?
|
| Virus Internalization | 2 | 2015 | 55 | 0.150 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2017 | 3 | 0.150 |
Why?
|
| Vietnam | 1 | 2017 | 48 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 473 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 141 | 0.140 |
Why?
|
| Aluminum Compounds | 2 | 2018 | 17 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2019 | 149 | 0.140 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 122 | 0.140 |
Why?
|
| Machine Learning | 1 | 2020 | 250 | 0.140 |
Why?
|
| Logistic Models | 4 | 2015 | 1800 | 0.140 |
Why?
|
| HIV Infections | 2 | 2019 | 1896 | 0.140 |
Why?
|
| Injections, Intramuscular | 3 | 2020 | 194 | 0.140 |
Why?
|
| Albuterol | 1 | 2017 | 52 | 0.140 |
Why?
|
| Phosphates | 2 | 2018 | 115 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2020 | 371 | 0.130 |
Why?
|
| Risk | 3 | 2019 | 759 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 6296 | 0.130 |
Why?
|
| Immunization Schedule | 4 | 2020 | 102 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1425 | 0.130 |
Why?
|
| Macrolides | 1 | 2016 | 29 | 0.130 |
Why?
|
| Interferons | 2 | 2017 | 126 | 0.130 |
Why?
|
| Azithromycin | 1 | 2016 | 43 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 177 | 0.130 |
Why?
|
| Cystitis | 1 | 1996 | 42 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1361 | 0.130 |
Why?
|
| Food Hypersensitivity | 1 | 2019 | 154 | 0.130 |
Why?
|
| Administration, Inhalation | 7 | 2020 | 180 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 398 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2017 | 829 | 0.120 |
Why?
|
| Feces | 2 | 2016 | 727 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2018 | 462 | 0.120 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2015 | 12 | 0.120 |
Why?
|
| Prevalence | 4 | 2015 | 2458 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 596 | 0.120 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 12 | 0.120 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 77 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 47 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Outpatients | 2 | 2021 | 250 | 0.120 |
Why?
|
| Molecular Typing | 3 | 2021 | 34 | 0.110 |
Why?
|
| Prognosis | 5 | 2015 | 4683 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 112 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 116 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2015 | 72 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 1708 | 0.110 |
Why?
|
| Papio | 4 | 2021 | 57 | 0.110 |
Why?
|
| Cough | 1 | 2015 | 94 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 2368 | 0.110 |
Why?
|
| Nasopharyngitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Proteobacteria | 1 | 2013 | 19 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2015 | 492 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3310 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1757 | 0.110 |
Why?
|
| Apnea | 1 | 2013 | 31 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5167 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2181 | 0.110 |
Why?
|
| Mass Vaccination | 1 | 2013 | 12 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2014 | 138 | 0.100 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2023 | 125 | 0.100 |
Why?
|
| Vaccines, Virosome | 1 | 2012 | 1 | 0.100 |
Why?
|
| Sf9 Cells | 1 | 2012 | 9 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2014 | 619 | 0.100 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 20 | 0.100 |
Why?
|
| Vaccines | 1 | 2017 | 366 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 5897 | 0.100 |
Why?
|
| Biotechnology | 1 | 2012 | 56 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 1252 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 319 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 77 | 0.100 |
Why?
|
| Immunization | 5 | 1997 | 308 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 1990 | 173 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2012 | 240 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 3 | 2014 | 339 | 0.100 |
Why?
|
| Cathelicidins | 3 | 2017 | 13 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 2054 | 0.090 |
Why?
|
| Picornaviridae | 1 | 2011 | 20 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2020 | 120 | 0.090 |
Why?
|
| Disease Susceptibility | 3 | 2024 | 299 | 0.090 |
Why?
|
| Cattle | 2 | 2024 | 562 | 0.090 |
Why?
|
| Vaccines, Subunit | 2 | 2021 | 66 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 3674 | 0.090 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2024 | 59 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 858 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3889 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 139 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2017 | 402 | 0.090 |
Why?
|
| Cross Reactions | 3 | 2004 | 191 | 0.090 |
Why?
|
| Otitis Media | 2 | 2009 | 85 | 0.080 |
Why?
|
| Serotyping | 2 | 2008 | 178 | 0.080 |
Why?
|
| School Health Services | 1 | 2010 | 99 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 1990 | 120 | 0.080 |
Why?
|
| Mice | 12 | 2025 | 17711 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 418 | 0.080 |
Why?
|
| Klebsiella | 1 | 1989 | 9 | 0.080 |
Why?
|
| Antibody Affinity | 2 | 2020 | 39 | 0.080 |
Why?
|
| Premature Birth | 1 | 2013 | 387 | 0.080 |
Why?
|
| Arvicolinae | 1 | 1989 | 4 | 0.080 |
Why?
|
| Malabsorption Syndromes | 1 | 1989 | 36 | 0.080 |
Why?
|
| Culture Techniques | 2 | 2004 | 82 | 0.080 |
Why?
|
| Short Bowel Syndrome | 1 | 1989 | 66 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2876 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 729 | 0.070 |
Why?
|
| DNA Primers | 3 | 2019 | 657 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 87 | 0.070 |
Why?
|
| Schools, Nursery | 1 | 2007 | 3 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 1989 | 128 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2020 | 776 | 0.070 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 106 | 0.070 |
Why?
|
| Genetic Therapy | 3 | 2002 | 687 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 791 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2005 | 316 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 356 | 0.070 |
Why?
|
| Chemokines | 1 | 2007 | 134 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2024 | 907 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 248 | 0.060 |
Why?
|
| Liver | 4 | 2002 | 1747 | 0.060 |
Why?
|
| Indazoles | 2 | 2015 | 25 | 0.060 |
Why?
|
| Metabolomics | 2 | 2020 | 422 | 0.060 |
Why?
|
| Aerosols | 3 | 2002 | 65 | 0.060 |
Why?
|
| Michigan | 1 | 2005 | 42 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 70 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 1986 | 114 | 0.060 |
Why?
|
| Livestock | 1 | 2024 | 12 | 0.060 |
Why?
|
| Farmers | 1 | 2024 | 12 | 0.060 |
Why?
|
| Sepsis | 1 | 1989 | 483 | 0.060 |
Why?
|
| Epitopes | 2 | 2018 | 432 | 0.060 |
Why?
|
| Office Visits | 1 | 2005 | 76 | 0.060 |
Why?
|
| Influenza in Birds | 1 | 2024 | 27 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2004 | 32 | 0.060 |
Why?
|
| Birds | 1 | 2024 | 85 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2024 | 18 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2024 | 67 | 0.050 |
Why?
|
| Registries | 1 | 2010 | 1434 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 473 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 1550 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 2007 | 354 | 0.050 |
Why?
|
| Escherichia coli | 1 | 1989 | 967 | 0.050 |
Why?
|
| Restriction Mapping | 1 | 2003 | 188 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3175 | 0.050 |
Why?
|
| Rotavirus | 1 | 2007 | 497 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2004 | 184 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3422 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1819 | 0.050 |
Why?
|
| Oxazines | 1 | 2023 | 25 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 2083 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 130 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2024 | 358 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 216 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2014 | 256 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 29 | 0.050 |
Why?
|
| A549 Cells | 1 | 2022 | 44 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2003 | 161 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2021 | 54 | 0.050 |
Why?
|
| Vaccines, Combined | 2 | 1995 | 39 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2022 | 36 | 0.050 |
Why?
|
| Turbinates | 1 | 2021 | 12 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2022 | 28 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2003 | 1109 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2021 | 35 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 372 | 0.050 |
Why?
|
| Immune System | 1 | 2002 | 90 | 0.050 |
Why?
|
| Vomiting | 1 | 2002 | 103 | 0.050 |
Why?
|
| Pyridines | 1 | 2023 | 235 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2013 | 478 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 23 | 0.050 |
Why?
|
| Species Specificity | 1 | 2022 | 549 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1893 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2021 | 211 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 1999 | 358 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 511 | 0.040 |
Why?
|
| Immune Sera | 1 | 2020 | 92 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 155 | 0.040 |
Why?
|
| Saponins | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hospitals, Pediatric | 2 | 2016 | 768 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2022 | 143 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 667 | 0.040 |
Why?
|
| Public Health | 1 | 2023 | 267 | 0.040 |
Why?
|
| Neutrophils | 2 | 2017 | 378 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2021 | 463 | 0.040 |
Why?
|
| Tablets | 1 | 2020 | 28 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 353 | 0.040 |
Why?
|
| Disease Management | 2 | 2014 | 528 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2020 | 51 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2020 | 57 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 176 | 0.040 |
Why?
|
| Decision Trees | 1 | 2020 | 50 | 0.040 |
Why?
|
| Cold Temperature | 4 | 2004 | 76 | 0.040 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2020 | 11 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2020 | 57 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2020 | 28 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2020 | 84 | 0.040 |
Why?
|
| Carnitine | 1 | 2020 | 74 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 42 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 156 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 728 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2020 | 153 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 1999 | 31 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2002 | 306 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 38 | 0.040 |
Why?
|
| Program Development | 1 | 2000 | 182 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 693 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 84 | 0.040 |
Why?
|
| DNA Probes | 1 | 2019 | 124 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 187 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 62 | 0.040 |
Why?
|
| Belgium | 1 | 2019 | 43 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 134 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2001 | 225 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1070 | 0.040 |
Why?
|
| Developed Countries | 1 | 2019 | 36 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 556 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 489 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 681 | 0.040 |
Why?
|
| Immunocompetence | 1 | 1998 | 33 | 0.040 |
Why?
|
| Alum Compounds | 2 | 1989 | 41 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 63 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 249 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 273 | 0.040 |
Why?
|
| Income | 1 | 2019 | 132 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 198 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 604 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2000 | 440 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 181 | 0.040 |
Why?
|
| World Health Organization | 1 | 2018 | 107 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2018 | 52 | 0.040 |
Why?
|
| Corynebacterium | 1 | 2017 | 9 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 37 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 2018 | 130 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 105 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2008 | 149 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1095 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 50 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 69 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 187 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 58 | 0.030 |
Why?
|
| Prevotella | 1 | 2016 | 8 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 260 | 0.030 |
Why?
|
| Reverse Genetics | 1 | 2016 | 15 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2016 | 72 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cholesterol | 1 | 1999 | 540 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 22 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 92 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 36 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2019 | 348 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 564 | 0.030 |
Why?
|
| Urinalysis | 1 | 1996 | 52 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 303 | 0.030 |
Why?
|
| Hematuria | 1 | 1996 | 54 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1996 | 77 | 0.030 |
Why?
|
| Cell Fusion | 1 | 2015 | 37 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 59 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 1999 | 1019 | 0.030 |
Why?
|
| Pichia | 1 | 2015 | 56 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 858 | 0.030 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nasal Decongestants | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mothers | 2 | 2015 | 356 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2018 | 376 | 0.030 |
Why?
|
| Antitussive Agents | 1 | 2015 | 3 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 246 | 0.030 |
Why?
|
| Expectorants | 1 | 2015 | 8 | 0.030 |
Why?
|
| Intubation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Bronchi | 1 | 2015 | 99 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 240 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 1833 | 0.030 |
Why?
|
| Tachypnea | 1 | 2015 | 1 | 0.030 |
Why?
|
| High-Frequency Ventilation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2014 | 3 | 0.030 |
Why?
|
| Environment | 1 | 1996 | 142 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1684 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 142 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 978 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 69 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 760 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 49 | 0.030 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1996 | 174 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 150 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2014 | 29 | 0.030 |
Why?
|
| Complement C1q | 1 | 2014 | 19 | 0.030 |
Why?
|
| Contig Mapping | 1 | 2014 | 55 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2004 | 3017 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 294 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 150 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 770 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2015 | 108 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 581 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 235 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2813 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 4595 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 471 | 0.030 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 121 | 0.030 |
Why?
|
| Sputum | 1 | 2013 | 106 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 390 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2017 | 677 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1084 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 766 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 802 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 76 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2011 | 118 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 166 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 479 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 887 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 1990 | 15 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2012 | 151 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 692 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1990 | 105 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 365 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 248 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 874 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1747 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1071 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1989 | 85 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1989 | 15 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 1990 | 142 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2525 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2008 | 29 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2002 | 4415 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 138 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2000 | 113 | 0.020 |
Why?
|
| Antigens | 1 | 1988 | 156 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1988 | 319 | 0.020 |
Why?
|
| Pollen | 1 | 1988 | 46 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2007 | 44 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 2007 | 35 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1907 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 131 | 0.020 |
Why?
|
| Pseudomonas Vaccines | 1 | 1986 | 1 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1538 | 0.020 |
Why?
|
| Mucus | 1 | 1986 | 36 | 0.020 |
Why?
|
| Comorbidity | 2 | 2004 | 1526 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 1986 | 89 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 1986 | 99 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 1988 | 185 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 1114 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 1986 | 134 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1986 | 170 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1989 | 303 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1986 | 162 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 2004 | 35 | 0.010 |
Why?
|
| Weight Loss | 1 | 2008 | 481 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 80 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 2007 | 348 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2004 | 288 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1997 | 1158 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2003 | 190 | 0.010 |
Why?
|
| Macrophages | 1 | 1986 | 626 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 968 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 615 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 146 | 0.010 |
Why?
|
| Platelet Count | 1 | 2002 | 137 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2001 | 53 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 364 | 0.010 |
Why?
|
| Korea | 1 | 2001 | 35 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 391 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 104 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2001 | 192 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 51 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2002 | 210 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2003 | 413 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 299 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 552 | 0.010 |
Why?
|
| Virulence | 1 | 2001 | 265 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 225 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 420 | 0.010 |
Why?
|
| APOBEC-1 Deaminase | 1 | 1999 | 12 | 0.010 |
Why?
|
| North America | 1 | 2000 | 243 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1614 | 0.010 |
Why?
|
| Helper Viruses | 1 | 1999 | 45 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2001 | 269 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 281 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2000 | 489 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 714 | 0.010 |
Why?
|
| Culture Media | 1 | 1998 | 180 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 763 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1701 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 3107 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 1999 | 235 | 0.010 |
Why?
|
| Gambia | 1 | 1996 | 28 | 0.010 |
Why?
|
| Virology | 1 | 1996 | 31 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 192 | 0.010 |
Why?
|
| Steroids | 1 | 1997 | 202 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1994 | 10 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1996 | 268 | 0.010 |
Why?
|
| Neoplasms | 1 | 1989 | 2790 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 292 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1996 | 242 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1994 | 92 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 3753 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 366 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 1180 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 1496 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 343 | 0.010 |
Why?
|
| Aluminum | 1 | 1988 | 12 | 0.000 |
Why?
|
| Sulfates | 1 | 1988 | 35 | 0.000 |
Why?
|